Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
About this item
Full title
Author / Creator
Publisher
New York: Nature Publishing Group US
Journal title
Language
English
Formats
Publication information
Publisher
New York: Nature Publishing Group US
Subjects
More information
Scope and Contents
Contents
Imatinib mesylate (Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous leukemia. Here we report ten individuals who developed severe congestive heart failure while on imatinib and we show that imatinib-treated mice develop left ventricular contractile dysfunction. Transmission electron micro...
Alternative Titles
Full title
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_853477816
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_853477816
Other Identifiers
ISSN
1078-8956
E-ISSN
1546-170X
DOI
10.1038/nm1446
